Biotech fundraising intensity continued to build as Revolution Medicines led a major capital raise and other companies moved toward public markets and new equity funding. The Revolution financing arrived as investor attention was already elevated after strong clinical performance signals in pancreatic cancer, illustrating how quickly market access can be re-priced when efficacy data land. Elsewhere in the capital stack, additional financings and IPO pipeline updates reflected renewed willingness from investors to fund riskier development-stage programs. The breadth of activity suggests continued demand for exposure to late-stage data, modality differentiation, and platform plays with near-term catalysts.